Our findings, as well as those of previous reports, support a critical role for TGF-β/SMAD signaling in the pathogenesis of renal disease and that targeting SMAD3 appears to be an attractive therapeutic option for immune-mediated nephritis, including lupus nephritis and anti-GBM nephritis. This evidence concerns the gene TGFB1 and kidney disorder.